gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BCYCHealthcarePharmaceuticals

Bicycle Therapeutics plc American Depositary Shares (BCYC)

$3.45−6.50%
Close Nov 12, 2026 · split-adjusted
Nov 11, 2026$3.69▼ 45.97% in range
Nov 11, 2025Low $3.38 · High $7.52Nov 11, 2026
What changed · written from our data
As of Nov 12, 2026

Bicycle Therapeutics plc American Depositary Shares closed at $3.45 on Nov 12, down 6.50%, within 2.1% of its 52-week closing low. Volume of 630.1K shares was 1.58× its 20-day average (above normal).

Split-adjusted performance: -1.7% over one month, -26.1% over six months, -49.5% over one year.

In the quarter ended Sep 30, 2026, revenue was $34.06M, up 190.2% from a year earlier, with a net margin of -30.8%.

Short interest was 3.9M shares at the Oct 30 settlement, up 11.7% from the prior report (8.4 days to cover).

Market cap$241.8M70.1M shares
Revenue · quarter$34.1M+190.2% YoY
Diluted EPS$-0.15—
P/E · TTM—P/S 2.9×
Net margin-30.8%Gross 100.0%
Dividend yieldNone
52-week range3.38 – 7.52−54.1% from high
Volume630.1K1.58× 20-day avg
Volatility · 60d58.1%Annualised
Short % of float—8.4 days to cover
Net cash$469.9MCash $469.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.9%1M −1.7%3M −11.5%6M −26.1%YTD −51.3%1Y −49.5%3Y −77.4%5Y −93.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 417 companies (100 = best)

6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size—

Industry medians: 6-month return −26.3%, revenue growth +9.3%, net margin −35.1%, P/E 16.5×.

Short interest

Details →
Shares short3.9M+11.7% vs prior
Days to cover8.4Settled Oct 30
% of float—
Short vol. 10d56.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BCYCBicycle Therapeutics$3.45−6.50%−26.1%+190.2%−30.8%—$241.8M
AMRNAmarin$11.67−0.34%−21.0%−20.4%0.6%—$490.6MCompare
KZIAKazia Therapeutics Limited$6.95−6.46%−49.7%———$108.1MCompare
MREOMereo BioPharma Group$0.3050−0.52%+24.0%———$48.7MCompare
SLNSilence Therapeutics Plc American Depository Share$19.80+0.15%+177.7%———$1.23BCompare
CMPSCOMPASS Pathways Plc American Depository Shares$9.12−1.94%−14.1%———$1.29BCompare
GPCRStructure Therapeutics$19.84−5.30%−50.2%———$1.41BCompare
ZLABZai Lab Limited$26.04−1.44%+28.1%−6.8%−42.6%—$3.22BCompare
QNRXQuoin Pharmaceuticals$3.75−0.27%−35.5%———$18.0MCompare

News about Bicycle Therapeutics

All news →

No recent articles focused on Bicycle Therapeutics. 1 articles mention it in passing.

Quick answers

What does Bicycle Therapeutics plc American Depositary Shares do?
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry.
What is BCYC's market cap?
$241.82M, based on the Nov 12 close of $3.45.
What sector is BCYC in?
Healthcare, in the Pharmaceuticals industry.

About Bicycle Therapeutics

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

HQ: Cambridge, X0288 employeesListed May 23, 2019bicycletherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology